



MALAYSIAN  
THORACIC  
SOCIETY



Malaysian  
Oncological  
Society

## LUNG CANCER SYMPOSIUM 2024

@ Royale Chulan Kuala Lumpur

26 - 28 April 2024



### FACULTY – BRIEF BIOGRAPHY



#### Dr. Fong Chin Heng

MD (USM), M.Clinical Oncology (UM), AM,  
Fellow (Princess Margaret Cancer Center, Toronto).

**Consultant Clinical Oncologist**

Penang General Hospital, Malaysia  
Gleneagles Hospital Penang, Malaysia.

Dr. Fong Chin Heng earned his MD degree from Universiti Sains Malaysia (USM) in 2003 and completed his formal training in the master's program in clinical oncology at Universiti Malaya in 2012. Following his specialization training, Dr. Fong devoted three years of service to Hospital Sultan Ismail in Johor Bahru, before returning to Penang General Hospital in 2015.

From 2018 to 2020, Dr. Fong undertook a clinical fellowship attachment at Princess Margaret Cancer Center in Toronto, Canada, focusing on innovative treatments for central nervous system tumors and brain metastasis, including gammaknife and volumetric arc therapy. He also specialized in genitourinary cancers, with an emphasis on MRI-guided high-dose rate brachytherapy for prostate cancer and stereotactic ablative radiotherapy. For his outstanding contributions, he was awarded the Best Fellow Award at Princess Margaret Cancer Hospital in 2020. Additionally, he received specialized training in the cyberknife technique from Erasmus University Medical Center in Rotterdam, Netherlands.

Currently, Dr. Fong serves as a consultant clinical oncologist at Penang General Hospital and Gleneagles Hospital Penang. He contributes to the education of future clinical oncologists through his involvement in the master of clinical oncology program and the national parallel pathway program, as well as the "train the trainer course" for the Malaysian national curriculum.

In addition to his clinical work, Dr. Fong is deeply involved in clinical research in various investigator-led and industry-sponsored phase 2 and 3 randomized clinical studies, including those in the central nervous system, genitourinary, lung, gastrointestinal, and breast, with a focus on novel treatment modalities such as immunotherapies, targeted therapies, and next-generation hormonal agents. His notable publications include quantitative assessments of MR LINAC-based image-guided radiotherapy and adaptations for stereotactic ablative radiotherapy in prostate cancer, as well as dosimetric evaluations of adult and pediatric brain tumors using mask-based gammaknife and volumetric modulated arc therapy.

#### Saturday, 27 April 2024

1) Speaker: SBRT for oligometastases

Time: 16:10 – 16:30